Fig. 1 · Structure
Documents & Downloads
DB1055
HOXA9 Inhibitor
DB1055 is a selective inhibitor of HOXA9 that interferes with its binding to DNA, effectively blocking its transcriptional activity. This compound demonstrates significant anti-leukemic effects by inducing cell growth reduction, apoptosis, and differentiation in human acute myeloid leukemia (AML) cells. DB1055 promotes monocyte-to-macrophage differentiation and exhibits efficacy in in vivo models using human THP-1 AML cells. Importantly, it does not affect human CD34+ bone marrow cells, making it a valuable tool for research in AML.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 869767-86-2 |
| Applications | HOXA9 Inhibitor |
| Formula | C21H18N6 |
| Molecular Weight | 354.42 |
| SMILES | N=C(N)C1=CC=CC(=C1)C=2C=CC(=CC2)C3=NC4=CC=C(C=C4N3)C(=N)N |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.